Jane Street Group LLC Has $321,000 Position in Ironwood Pharmaceuticals, Inc. (IRWD)

Jane Street Group LLC reduced its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 32.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,383 shares of the biotechnology company’s stock after selling 9,767 shares during the period. Jane Street Group LLC’s holdings in Ironwood Pharmaceuticals were worth $321,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Gerber Kawasaki Wealth & Investment Management purchased a new stake in Ironwood Pharmaceuticals in the 3rd quarter worth $170,000. Teacher Retirement System of Texas purchased a new stake in Ironwood Pharmaceuticals in the 2nd quarter worth $192,000. Strs Ohio increased its holdings in Ironwood Pharmaceuticals by 63.1% in the 2nd quarter. Strs Ohio now owns 10,600 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 4,100 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in Ironwood Pharmaceuticals by 5.8% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 648 shares in the last quarter. Finally, Aperio Group LLC increased its holdings in Ironwood Pharmaceuticals by 11.9% in the 2nd quarter. Aperio Group LLC now owns 13,213 shares of the biotechnology company’s stock worth $249,000 after acquiring an additional 1,410 shares in the last quarter.

In other news, CEO Peter M. Hecht sold 113,405 shares of the company’s stock in a transaction on Thursday, December 7th. The shares were sold at an average price of $15.12, for a total transaction of $1,714,683.60. Following the completion of the sale, the chief executive officer now owns 4,696,917 shares of the company’s stock, valued at $71,017,385.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 115,769 shares of company stock valued at $1,752,491 in the last ninety days. Insiders own 7.63% of the company’s stock.

Several equities research analysts recently commented on IRWD shares. BidaskClub raised shares of Ironwood Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Credit Suisse Group started coverage on shares of Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 price target for the company. ValuEngine lowered shares of Ironwood Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 14th. Mizuho reissued a “buy” rating and issued a $20.00 price target (down previously from $23.00) on shares of Ironwood Pharmaceuticals in a report on Friday, August 25th. Finally, Morgan Stanley reissued a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $17.88.

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ IRWD) opened at $15.46 on Thursday. Ironwood Pharmaceuticals, Inc. has a 1-year low of $13.43 and a 1-year high of $19.94. The company has a debt-to-equity ratio of -22.31, a quick ratio of 4.86 and a current ratio of 4.87.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.07. Ironwood Pharmaceuticals had a negative net margin of 48.89% and a negative return on equity of 645.22%. The business had revenue of $86.80 million during the quarter, compared to analyst estimates of $73.59 million. During the same quarter in the prior year, the firm earned ($0.18) earnings per share. The company’s revenue for the quarter was up 31.3% compared to the same quarter last year. analysts expect that Ironwood Pharmaceuticals, Inc. will post -1.12 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Jane Street Group LLC Has $321,000 Position in Ironwood Pharmaceuticals, Inc. (IRWD)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/21/jane-street-group-llc-has-321000-position-in-ironwood-pharmaceuticals-inc-irwd.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Institutional Ownership by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit